Abstract: A method for prognostic or diagnostic assessment of a gastrointestinal-related disorder, such as ulcerative colitis, in a subject correlates the presence, absence, and/or magnitude of a gene in a sample with a reference standard to determine the presence and/or severity of the disorder, and/or the response to treatment for the disorder. The method enables identification of the effectiveness of candidate therapies.
Abstract: The present invention is directed to pluripotent cells that can be readily expanded in culture on tissue culture substrate that is not pre-treated with protein or an extracellular matrix, and do not require a feeder cell line. The present invention also provides methods to derive the pluripotent cell line from human embryonic stem cells.
Abstract: The present invention provides methods to produce pluripotent stem cells from adult cells. In particular, the present invention provides methods to produce pluripotent stem cells from somatic cells without the use of a feeder-cell layer or an agent that increases efficiency of retroviral transfection.
Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
Type:
Grant
Filed:
December 28, 2006
Date of Patent:
May 3, 2011
Assignee:
Centocor Ortho Biotech Inc.
Inventors:
Jacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya I. Orlovsky, Robert Rauchenberger, Raymond Sweet
Abstract: Isolated polynucleotides encoding cynomolgus monkey gp80, polypeptides obtainable from expression of these polynucleotides, compositions, recombinant cells, methods of making and using these polynucleotides, polypeptides, and compositions are useful in development of human therapeutics.
Type:
Grant
Filed:
May 21, 2009
Date of Patent:
April 26, 2011
Assignee:
Centocor Ortho Biotech Inc.
Inventors:
Michael Naso, Ronald Swanson, Bethany Swencki-Underwood
Abstract: Compounds of formula I: wherein: R2 is hydrogen or C1-C4alkyl; R3 and R4 are hydrogen, —C(?O)R5, or —C(?O)CHR6—NH2; or R3 is hydrogen and R4 is a monophosphate-, diphosphate-, or triphosphate ester; or R3 is hydrogen, —C(?O)CHR5, or —C(?O)CHR6—NH2 and R4 is each R5 is hydrogen, C1-C6alkyl, or C3-C7cycloalkyl; R6 is hydrogen or C1-C6alkyl; R7 is optionally substituted phenyl; naphthyl; or indolyl; R8 and R8? are hydrogen, C1-C6alkyl, benzyl; or R8 and R8? combined form C3-C7cycloalkyl; R9 is C1-C6alkyl, benzyl, or optionally substituted phenyl; provided that R2, R3 and R4 are not all hydrogen; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical formulations with the compounds I; the use of compounds I, including the compounds of formula I wherein R2, R3 and R4 are all hydrogen, as HCV inhibitors.
Type:
Application
Filed:
July 1, 2009
Publication date:
April 21, 2011
Applicants:
CENTOCOR ORTHO BIOTECH PRODUCTS L.P., MEDIVIR AB
Inventors:
Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck
Abstract: Disclosed is a device for the parenteral delivery of a medication, such as a drug. The device includes upper and lower housings in which the upper housing is configured to move relative to the lower housing as a result of application of an external force to permit the user of the device to control the rate at which the drug is administered.
Type:
Application
Filed:
October 15, 2010
Publication date:
April 21, 2011
Applicant:
Centocor
Inventors:
Lorin P. Olson, Peter Krulevitch, James Glencross, Jingli Wang, Nicholas Foley, Mingqi Zhao
Abstract: Melanocortin receptor binding mimetibody polypeptides are disclosed. Polynucleotides encoding these polypeptides, cells comprising these polynucleotides or expressing the mimetibodies, and methods of making and using the forgoing are also disclosed.
Type:
Grant
Filed:
October 30, 2007
Date of Patent:
March 22, 2011
Assignee:
Centocor, Inc.
Inventors:
Mark Cunningham, Vedrana Stojanovic-Susulic, Karyn O'Neil, Chichi Huang, Jeffrey Luo
Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders.
Type:
Grant
Filed:
July 9, 2009
Date of Patent:
February 15, 2011
Assignee:
Centocor Ortho Biotech Inc.
Inventors:
Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
Abstract: Isolated polynucleotides encoding Macaca fascicularis ST2L (Cyno ST2L), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.
Type:
Grant
Filed:
March 31, 2009
Date of Patent:
February 1, 2011
Assignee:
Centocor Ortho Biotech, Inc.
Inventors:
Adam Cotty, Natalie Fursov, Michael Naso
Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Type:
Grant
Filed:
October 30, 2007
Date of Patent:
November 16, 2010
Assignee:
Centocor, Inc.
Inventors:
Jill Giles-Komar, David Knight, David Peritt, Mohit Trikha
Abstract: The present invention provides to at least one novel human GLP-1 receptor agonist, or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 receptor agonist, or specified portion or variant, GLP-1 receptor agonist, or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including the use of long acting GLP-1 receptor agonists to improve insulin sensitivity or lipid profiles in obesity and related therapeutic and/or diagnostic compositions, methods and devices.
Type:
Grant
Filed:
December 21, 2007
Date of Patent:
November 16, 2010
Assignee:
Centocor, Inc.
Inventors:
Karyn T. O'Neil, Kristen Picha, Vedrana Stojanovic-Susulic
Abstract: The present invention relates to inhibiting TNF in patients having rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis, by administering anti-TNF antibodies comprising the heavy chain variable region of SEQ ID NO: 7 and the light chain variable region of SEQ ID NO:8, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof.
Type:
Grant
Filed:
November 11, 2008
Date of Patent:
October 26, 2010
Assignee:
Centocor, Inc.
Inventors:
George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
Abstract: The present invention relates to inhibiting TNF in patients having rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis, by administering anti-TNF antibodies comprising the heavy chain variable region of SEQ ID NO: 7 and the light chain variable region of SEQ ID NO:8, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof.
Type:
Grant
Filed:
November 13, 2008
Date of Patent:
October 19, 2010
Assignee:
Centocor, Inc.
Inventors:
George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
Abstract: An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
Type:
Grant
Filed:
February 13, 2009
Date of Patent:
October 5, 2010
Assignee:
Centocor Ortho Biotech Inc.
Inventors:
Jacqueline Benson, Mark Cunningham, Cynthia Duchala, Jill M. Giles-Komar, Jinquan Luo, Michael A. Rycyzyn, Sweet Raymond
Abstract: An anti-IL-23 specific human Ig derived protein, isolated nucleic acids that encode at least one anti-IL-23 Ig derived protein, vectors, host cells, transgenic animals or plants, and methods of making and using thereof are useful as therapeutic and diagnostic compositions, methods and devices. The anti-IL-23 Ig derived protein preferably binds to one or more of the Seg 1, Seg 2, and Seg 3 epitopes of the p40 subunit of IL-23.
Type:
Grant
Filed:
June 26, 2007
Date of Patent:
October 5, 2010
Assignee:
Centocor Ortho Biotech, Inc.
Inventors:
Jacqueline Benson, Mark Cunningham, Jeffrey (Sinquan) Luo
Abstract: The invention relates to a method of directing selection of biological therapeutic molecules to specific functional domains of the target biologic molecule. Selection is directed by the use of closely related molecules, where one is a decoy and the other contains the targeted domain or epitope. The invention is based on the use of physical data, which may be combined with derived data, to ascertain that the decoy and the target differ only in the specific functional domain or epitope where the binding will be directed.
Type:
Grant
Filed:
April 22, 2005
Date of Patent:
September 7, 2010
Assignee:
Centocor, Inc.
Inventors:
Karyn O'Neil, Raymond Sweet, George Heavner
Abstract: The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CFR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation.
Type:
Grant
Filed:
October 29, 2007
Date of Patent:
August 17, 2010
Assignee:
Centocor, Inc.
Inventors:
Linda K. Joliffe, Robert A. Zivin, Virginia L. Pulito
Abstract: Methods for treating pathological pulmonary conditions and bleomycin associated pulmonary fibrosis administer IL-16 antagonists, for example, anti-IL-16 antibodies, to subjects.